Comparative Efficacy of Goserelin vs. Leuprolide in Advanced Prostate Cancer in Patients Undergoing Androgen Deprivation Therapy


  • Muhammad Adnan Zeb Department of Oncology, Combined Military Hospital Rawalpindi Pakistan
  • Zeeshan Ahmed Alvi Department of Oncology, Combined Military Hospital Rawalpindi Pakistan
  • Muhammad Imran Khan Wajid Department of Oncology, Combined Military Hospital Rawalpindi Pakistan
  • Sameed Hussain Department of Oncology, Combined Military Hospital Rawalpindi Pakistan
  • Omer Riaz Department of Oncology, Combined Military Hospital Rawalpindi Pakistan



Advanced prostate cancer, castration, Goserelin, Leuprolide, CAB complete androgen blockade, ADT androgen deprivation therapy



Objectives: To determine the efficacy (achievement of castrate testosterone level at six months) of LHRH agonist therapy with different agonists, i.e., Leuprolide vs. Goserelin.

Study Design: Quasi-experimental study.

Place and Duration of Study: Radiation Oncology Department, Combined Military Hospital Rawalpindi Pakistan, from Jan to Oct 2020.

Methodology: One hundred and seventy-eight patients (n=178) having histopathologically confirmed prostate adenocarcinoma, aged 60 to 80 years, with eastern cooperative oncology group (ECOG) performance status ≤2, men with advanced prostate cancer were randomly assigned to receive different treatment, group 1(89) patients received Goserelin. 3.6mg vs group 2(89) received Leuprolide 7.5mg. The study achieved 100 % accrual in the initial 2.5 months from the start of the study. Each agent was injected intramuscularly six times every 28 days for six injections. The percentage of men whose serum testosterone concentrations fell to and remained at or below castrate levels was the primary endpoint.

Results: Analysis was made on 178 patients in this study. No statistically significant difference was observed between the two groups in terms of achievement of castration levels of testosterone (Leuprolide 98.9% vs. Goserline 88.7%, respectively: p=0.126) from baseline to 6 months. The chi-square test was applied to the outcome in both groups, and results were found to be insignificant statistically (p=0.126).

Conclusion: In this study, no significant difference was determined between groups in attaining and maintaining castration levels of serum testosterone at six months.


Download data is not yet available.


Metrics Loading ...


Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012; 61(1): 11-25.

Rick FG, Block NL, Schally AV. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opin Pharmacother 2013; 14(16) :2237-2247.

Newton CL, Riekert C, Millar RP. Gonadotropin-releasing hormone analog therapeutics. Minerva Ginecol 2018; 70(5): 497-515.

Descotes JL. Diagnosis of prostate cancer. Asian J Urol 2019; 6(2): 129-136.

Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med 2018; 8(12): a030361.

Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 2017; 317(24): 2532-2542.

Catalona WJ. Prostate cancer screening. Med Clin N Am 2018: 102(2): 199-214.

Mahmood S, Qasmi G, Ahmed A, Kokab F, Zahid MF, Afridi MI, et al. Lifestyle factors associated with the risk of prostate cancer among Pakistani men. J Ayub Med Coll Abbottabad 2012; 24(2): 111-115.

Fujita K, Nonomura N. [Treatment of Advanced Prostate Cancer] Gan To Kagaku Ryoho 2020; 47(1): 27-29.

Yikilmaz TN, Ozturk E, Hizli F, Hamidi N, Basar H. Effect of hormonal therapy for volume reduction, lower urinary tract symptom relief and voiding symptoms in prostate cancer: leuprolide vs goserelin. Urol J 2019; 16(2): 157-161.

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 2019; 22(1): 24-38.

Evans AJ. Treatment effects in prostate cancer. Mod Pathol 2018; 31(S1): S110-121.

Nevedomskaya E, Baumgart SJ, Haendler B. Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int J Mol Sci 2018; 19(5): 1359.

. Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019; 30(12): 1992-2003.

Barata PC, Sartor AO. Metastatic castration-sensitive prostate cancer: Abiraterone, Docetaxel, or Cancer 2019; 125(11): 1777-1788.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, et al. TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019; 381(1): 13-24.

Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, et al. Is There a Role for Immunotherapy in Prostate Cancer? Cells 2020; 9(9): 2051.

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20(3): 408-419.




How to Cite

Zeb MA, Zeeshan Ahmed Alvi, Muhammad Imran Khan Wajid, Sameed Hussain, Omer Riaz. Comparative Efficacy of Goserelin vs. Leuprolide in Advanced Prostate Cancer in Patients Undergoing Androgen Deprivation Therapy. Pak Armed Forces Med J [Internet]. 2024 Apr. 29 [cited 2024 May 24];74(2):540-3. Available from:



Original Articles

Most read articles by the same author(s)